Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT05382884 Completed - Clinical trials for Postpartum Depression

The SUPPORT Study: Effectiveness and Usability of a Web-Enabled Resource for Postpartum Mental Health

SUPPORT
Start date: April 20, 2022
Phase: Phase 2
Study type: Interventional

The SUPPORT Study aims to evaluate the effectiveness and usability of postpartumcare.ca, a web-enabled resource for postpartum depression (PPD) and postpartum anxiety (PPA), created based on the input of birthing parents in British Columbia (BC) affected by these disorders.

NCT ID: NCT05376150 Completed - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

X-NOVA
Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.

NCT ID: NCT05375214 Completed - Bipolar Depression Clinical Trials

iTBS in Bipolar I Depression

Start date: March 3, 2023
Phase: N/A
Study type: Interventional

A multisite, open label pilot study to investigate the efficacy and safety of a novel accelerated intermittent theta-burst stimulation (iTBS) protocol while assessing for changes in neuroimaging biomarkers associated with treatment response.

NCT ID: NCT05373329 Completed - Depression, Anxiety Clinical Trials

Testing a Digital Health Intervention App for Depression and Anxiety

Start date: June 14, 2021
Phase: N/A
Study type: Interventional

Although mobile applications ("apps") for mental health are popular and widely available, little is known about how well they actually help people with common mental health symptoms of depression, anxiety, and stress. We are partnering with a commercially available app to test how well this app helps people's mental health over 8 weeks. Participants will be randomly assigned (like flipping a coin) to two groups: (a) using the app, (b) no app until after 8 weeks. We will ask participants to complete online surveys about their mood and well-being so we can better understand the effects of these different treatments.

NCT ID: NCT05356026 Completed - Clinical trials for Postpartum Depression

Online Postpartum Follow-up on Depression and Postpartum Adaptation

Start date: March 10, 2021
Phase: N/A
Study type: Interventional

Objective: To determine the effect of online postpartum follow-up on depression and postpartum adaptation. Design: A parallel-randomized-controlled study Setting: During 2021 in Turkey Participants: 52 women in the postpartum period Measurements: Data were collected through the Personal Information Form, the Follow-up Form, the Edinburgh Postpartum Depression Scale (EPDS), and the Postpartum Self-Assessment Scale (PSAS). The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk. The women in the control group received the routine follow-up and care provided by the hospital.

NCT ID: NCT05355285 Completed - Clinical trials for Major Depressive Disorder

Type 1 Diabetes and Depression: Role of Brain Glutamate

Start date: January 2011
Phase: N/A
Study type: Interventional

The goal of this study is to examine the effect of chronic and acute hyperglycemia in type 1 diabetes mellitus (T1DM) on brain glutamate levels using magnetic resonance spectroscopy (MRS), and associations of brain glutamate with symptoms of depression.

NCT ID: NCT05347199 Completed - Clinical trials for Major Depressive Disorder

Effects of a Single Dose of Amisulpride on Functional Brain Changes

Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

This study is designed to investigate effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing and at rest in healthy volunteers (HV) and in patients with Major Depressive Disorder (MDD).

NCT ID: NCT05335564 Completed - Depressive Disorder Clinical Trials

Evaluation of a Website to Improve Depression Literacy in Parents of Adolescents With Depression

Start date: January 20, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the efficacy and acceptability of the website "ich bin alles" (https://www.ich-bin-alles.de/) to improve depression literacy (knowledge about depression, which aid the recognition, treatment or prevention of depression) in parents of adolescents with acute or remitted depressive disorder. The investigators will examine whether the website improves depression literacy in parents of adolescents aged 12 to 18 years with a history of depression. The investigators will also assess the acceptability of the website among the participants.

NCT ID: NCT05326178 Completed - Depressive Disorder Clinical Trials

Evaluation of a Website to Improve Depression Literacy in Parents of Healthy Adolescents

Start date: January 12, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the efficacy and acceptability of the website "ich bin alles" (https://www.ich-bin-alles.de/) to improve depression literacy (knowledge about depression, which aid the recognition, treatment or prevention of depression) in parents of healthy adolescents without a mental health condition. The investigators will examine whether the website improves depression literacy in parents of adolescents aged 12 to 18 years without a mental health condition. The investigators will also assess the acceptability of the website among the participants.

NCT ID: NCT05324735 Completed - Clinical trials for Resistant Major Depression

Pentoxifylline for Treatment of Resistant Major Depression

Start date: December 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A growing body of evidence has highlighted the role of inflammation and phosphodiesterases (PDE)-related pathways in the pathogenesis of neuropsychiatric illnesses such as depression/mood disorders. Herein, we aimed to evaluate the therapeutic benefits of pentoxifylline (PTX) in the treatment of therapy-resistant depression (TRD) in adult patients with bipolar depression.